Proactive Investors - Run By Investors For Investors

Arix Bioscience confirms Autolus to launch proposed public offering

The final price has not yet been set but Autolus is planning on issuing up to 4.6mln American Depositary Shares (ADS) as part of the offering
Nasdaq
Autolus was spun out from University College London in 2014

Biotech investor Arix Bioscience PLC (LON:ARIX) has confirmed that its investee company, Autolus Therapeutics PLC (NASDAQ:AUTL), has announced the launch of a proposed public offering in the United States.

The proposed maximum aggregate offering amount specified in the filing is 4mln American Depositary Shares (ADS), which does not include the underwriters’ option to purchase 600,000 additional ADS.

Each ADS represents one ordinary share. The final price per ADS in the offering will be determined following a book building process.

Arix shares were unchanged on Tuesday at 143p.

View full ARIX profile View Profile

Arix Bioscience PLC Timeline

Related Articles

PT exercises
December 19 2018
The Californian company is a bet on an industry that is in need of transformation
LX2 analyzer
May 07 2019
Armed with promising study results and proven technology, LexaGene is getting ready to launch the LX2 Genetic Analyzer to underserved markets valued at an estimated US$40 billion
researcher
April 30 2019
We take a look at a company with a unique approach to drug development that may ultimately help big pharma replenish its pipeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use